CSIMarket Company Name, Ticker, Competitors, else..
 
Cabaletta Bio Inc   (NASDAQ: CABA)
Other Ticker:  
 
 
Price: $2.0300 $0.22 12.155%
Day's High: $2.16 Week Perf: 57.36 %
Day's Low: $ 1.65 30 Day Perf: 74.25 %
Volume (M): 15,897 52 Wk High: $ 13.50
Volume (M$): $ 32,272 52 Wk Avg: $4.24
Open: $2.14 52 Wk Low: $0.99



 Market Capitalization (Millions $) 103
 Shares Outstanding (Millions) 51
 Employees 36
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 1

Cabaletta Bio Inc
Cabaletta Bio Inc is a clinical-stage biotechnology company that focuses on the development of gene therapies for treating patients with B cell-mediated autoimmune diseases. Their proprietary technology platform utilizes chimeric autoantibody receptor (CAAR) T cells to selectively eliminate specific autoreactive B cells, which are responsible for causing autoimmune diseases. By genetically engineering a patient's own T cells to express specific CAARs, Cabaletta aims to provide long-term remission or a potential cure for diseases such as mucosal pemphigus vulgaris and mucosal PV. The company is actively engaged in conducting clinical trials to validate the efficacy and safety of their gene therapies.


   Company Address: 2929 Arch Street Philadelphia 19104 PA
   Company Phone Number: 759-3100   Stock Exchange / Ticker: NASDAQ CABA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        2% 
EXEL        21.49% 
GILD        4.66% 
IMCR        2.78% 
MRNA   -3.27%    
NVAX        6.15% 
• View Complete Report
   



Clinical Study

Promising Advances in Autoimmune Treatment Cabaletta Bios CABA-201 Shows Deepening Clinical Efficacy and Secures Orp...

Published Tue, Feb 18 2025 6:33 PM UTC

Cabaletta Bio, a clinical-stage biotechnology company, is making significant strides in the development of innovative targeted cell therapies aimed at treating autoimmune diseases. Recent updates from the company highlight the encouraging clinical performance of their investigational therapy, CABA-201, particularly across a range of indications such as systemic lupus erythem...
Clinical Study

Pioneering Advances in Autoimmune Therapies Cabaletta Bios Revelation of CABA-201s Promising Profile

Published Mon, Nov 18 2024 12:01 PM UTC

In the expansive realm of autoimmune therapeutics, the quest for efficient, targeted treatments continues unabated. As research and clinical trials advance, each incremental step uncovers new possibilities and refines our understanding of how these complex diseases can be effectively managed. A significant stride was recently made at the ACR Convergence 2024, where Cabalet...
Clinical Study

Cabaletta Bios CABA-201 shows promising safety profile in Phase 1/2 trials for myositis and SLE

Published Fri, Jun 14 2024 6:00 AM UTC

Cabaletta Bio, a clinical-stage biopharmaceutical company, has recently released positive initial clinical data from their Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201. The company reported that there were no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, or serious adverse events observed in...
Clinical Study

Cabaletta Bio's Breakthrough: FDA Grants Orphan Drug Designation to CABA-201, Paving the Way for Systemic Sclerosis Treatment Revolution

Published Wed, Mar 20 2024 11:00 AM UTC

Cabaletta Bio Receives FDA Orphan Drug Designation for CABA-201 in Systemic Sclerosis TreatmentPhiladelphia-based biotechnology company, Cabaletta Bio, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for their investigational therapy, CABA-201, intended for the treatment of systemic sclerosis (SSc). This exciting development mark...
Product Service News

Cabaletta Bio's CABA-201 Receives FDA Orphan Drug Designation for the Treatment of Myositis: A Promising Breakthrough in Autoimmune Disease Therapy

Published Thu, Feb 1 2024 9:30 PM UTC

Cabaletta Bio Receives FDA Orphan Drug Designation for CABA-201 in the Treatment of MyositisCabaletta Bio, a leading biotechnology company focused on developing breakthrough targeted cell therapies for autoimmune diseases, has recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CABA-201 for the treatment of idiopathic in...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com